CA2335713C - Oral dosage form - Google Patents
Oral dosage form Download PDFInfo
- Publication number
- CA2335713C CA2335713C CA002335713A CA2335713A CA2335713C CA 2335713 C CA2335713 C CA 2335713C CA 002335713 A CA002335713 A CA 002335713A CA 2335713 A CA2335713 A CA 2335713A CA 2335713 C CA2335713 C CA 2335713C
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- gelatine capsule
- polyunsaturated fatty
- recited
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000006186 oral dosage form Substances 0.000 title claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 32
- 239000001828 Gelatine Substances 0.000 claims abstract description 24
- 229920000159 gelatin Polymers 0.000 claims abstract description 24
- 235000019322 gelatine Nutrition 0.000 claims abstract description 24
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 235000005911 diet Nutrition 0.000 claims abstract description 6
- 230000000378 dietary effect Effects 0.000 claims abstract description 6
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 6
- 239000003921 oil Substances 0.000 claims description 19
- 235000019198 oils Nutrition 0.000 claims description 19
- 235000004347 Perilla Nutrition 0.000 claims description 17
- 239000002552 dosage form Substances 0.000 claims description 14
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 6
- 235000019197 fats Nutrition 0.000 claims description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 5
- 235000021323 fish oil Nutrition 0.000 claims description 4
- 235000021388 linseed oil Nutrition 0.000 claims description 4
- 239000000944 linseed oil Substances 0.000 claims description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 4
- 238000005502 peroxidation Methods 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 3
- 229960002733 gamolenic acid Drugs 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 244000124853 Perilla frutescens Species 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 17
- 150000007513 acids Chemical class 0.000 abstract description 14
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 22
- 241000229722 Perilla <angiosperm> Species 0.000 description 16
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 11
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010016766 flatulence Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- XPNLOZNCOBKRNJ-UHFFFAOYSA-N ethyl prop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C=C.COC(=O)C(C)=C XPNLOZNCOBKRNJ-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- General Preparation And Processing Of Foods (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Oral dosage form for food and food supplement as well as dietetics comprisi ng polyunsaturated acids in a xylose-hardened gelatine capsule with a retarded release time.
Description
Oral Dosage Form The present invention relates to an oral dosage form for food, food supplement, and dietetics.
In the field of food supplement, dietetics and drugs the use of omega-3 polyunsatu-rated acids is known. Fish oil, linseed oil, cod-liver oil or the like is used to provide said polyunsaturated acids. It is known to supply said substances in gelatine capsules to control the unpleasant taste and to avoid flatulences. To reduce the risk of rapid oxidation and thereby the risk of enlarged toxicity, the oil is mixed with anti-oxidants. Rapid oxidation (becoming rancid) causes not only the development of unhealthy radicals but also reduces the durability of the products. A further problem is the risk that polyunsaturated acids are subject to undesired changes in the stomach and in the duodenum before they enter the small intestine, whereby said acids are not or only partly available in the location of resorption.
W090/04391 discloses an oral dosage form of omega-3 polyunsaturated acids to overcome the problems of vascular diseases. It is known to supply said acids in soft gelatine capsule shells. W096/36329 discloses to provide gelatine capsules with a coat of poly ethyl acrylate-methyl-methacrylate. The coat prevents releasing of acid from the capsule already in the stomach.
A pure gelatine capsule prevents neither the risk of changes in the structure of the polyunsaturated acids nor undesired flatulences together with its unpleasant smell.
./2 EP 2 240 581 B 1 discloses a gelatine capsule for pharmaceutical use with a con-trolled release of active ingredients and a process for the preparation of said gelatine capsules. During said process xylose is added to the liquid gelatine from which afterwards gelatine capsules are formed. Gelatine capsules manufactured according to the process provide retarded release of active ingredients.
The underlying problem of the invention is to provide an oral dosage form for poly-unsaturated acids comprising food, food supplement, and dietetics which provides a longer durability for the polyunsaturated acids. Furthermore, the oral dosage form should be admissible under food regulations.
The problem is solved with the features of claim 1.
According to the present invention, polyunsaturated acids are provided in gelatine capsules. The gelatine capsule is hardened with the help of xylose. The hardening provides a retarded opening time of the capsule from about 45 minutes and more Typically fatty acids are mixed with antioxidants such as tocopherole, ascorbyl-palmitate, propyl gallate and the like. The addition of antioxidants is avoided according to the invention because the xylose hardening prevents fat from "going bad". The peroxidation of the unsaturated acids is an important reaction for going bad of fat. Surprisingly, the dosage form according to the invention provides a low peroxidation, and a considerable delay in time for the fat to become rancid.
The oral dosage form according to the invention provides an undisturbed release of polyunsaturated acids in the intestine after passing the stomach. An unpleasant smell and flatulences are prevented.
.../3 Xylose is a well-known adjuvant in food industry which is inter alia re-claimable waste of the cellulose production. Xylose is also suitable as sweetening agent.
Furthermore, xylose has a laxative effect.
Omega-3 polyunsaturated acids with a high content of alpha linolenic acid, preferred perilla oil, can be used as polyunsaturated fatty acids. Also the use of fish oil, linseed oil, and gamma-linolenic acid is preferred.
The dosage form according to the invention is very well suited for essential fatty acids of all kinds which are delicate to formation of toxic radicals. For the use of the dosage form the following requirements hold:
- peroxide value < 2, - no advanced decomposition in the stomach or in the duodenum, - resorption in the small intestine.
Surprisingly all these requirements are achieved with the dosage form according to the invention.
According to a preferred embodiment of the invention the gelatine capsule is filled with perilla oil. Perilla oil is gained from the oil-containing fruits of the Asian plant perilla fructuence. The perilla oil contains more than 70% of unsaturated fatty acids, in particular a-linolenic acid.
A plurality of scientific studies has proven positive effects for the metabolism of fat (metabolic syndrome) and an antiphlogistic effect in the intestine (Morbus Crohn).
Perilla oil has furthermore the advantage of being almost without taste and smell.
.../4 Two galenic forms, a pure gelatine capsule and a xylose-hardened capsule, each containing perilla oil, have been tested for their peroxide value at 20°C and 45%
humidity for a time period of 12 months. The peroxide value of the xylose-hardened capsule was significantly lower than that of the pure gelatine capsule and did not increase during the testing period but even decreased.
In the study 24 persons took 3 to 6 capsules a 500 mg perilla oil over 4 weeks, no nausea, no stomach pressure, or other symptoms were observed. The persons' ability to taste was not reduced.
Example:
500 mg perilla oil capsule without xylose hardening during the long term test:
0 Months 3 Months6 Months 12 Months Perilla Oil / Perilla 498.2 506.2 513.5 486.1 Oil mg Perilla Oil / a-Linolenic260 264.2 268 253.7 Acid mg Peroxide Value 2.3 2.5 3.1 3 500 mg perilla oil capsule with xylose hardening during the long term test:
0 Months 3 Months6 Months 12 Months Perilla Oil / Perilla 498.7 508.1 513.8 489.2 Oil mg Perilla Oil / a-Linolenic260.3 265.2 268.2 255.5 Acid mg Peroxide Value 2.1 2.1 1.6 1 Blister packaging was used during the long term test.
./5 Xylose hardening can be achieved according to EP 0 240 581 B1, especially according to Example 3 of the specification. In an alternative approach it is possible to uniformly spray the capsule with a solution comprising xylose, ethanol and water for a predetermined time interval. During this time the capsules are heated.
After spraying a predetermined amount of hardening solution, the capsules are heat-treated for a predetermined time interval. The heat treatment causes the aldehyd function of the xylose to react with the gelatine and to provide a cross-linking. The cross-linking causes the hardening of the gelatine capsule. The finished product provides a struc-ture which inhibits the peroxidation of fatty acids so that the addition of antioxidants is unnecessary.
./6
In the field of food supplement, dietetics and drugs the use of omega-3 polyunsatu-rated acids is known. Fish oil, linseed oil, cod-liver oil or the like is used to provide said polyunsaturated acids. It is known to supply said substances in gelatine capsules to control the unpleasant taste and to avoid flatulences. To reduce the risk of rapid oxidation and thereby the risk of enlarged toxicity, the oil is mixed with anti-oxidants. Rapid oxidation (becoming rancid) causes not only the development of unhealthy radicals but also reduces the durability of the products. A further problem is the risk that polyunsaturated acids are subject to undesired changes in the stomach and in the duodenum before they enter the small intestine, whereby said acids are not or only partly available in the location of resorption.
W090/04391 discloses an oral dosage form of omega-3 polyunsaturated acids to overcome the problems of vascular diseases. It is known to supply said acids in soft gelatine capsule shells. W096/36329 discloses to provide gelatine capsules with a coat of poly ethyl acrylate-methyl-methacrylate. The coat prevents releasing of acid from the capsule already in the stomach.
A pure gelatine capsule prevents neither the risk of changes in the structure of the polyunsaturated acids nor undesired flatulences together with its unpleasant smell.
./2 EP 2 240 581 B 1 discloses a gelatine capsule for pharmaceutical use with a con-trolled release of active ingredients and a process for the preparation of said gelatine capsules. During said process xylose is added to the liquid gelatine from which afterwards gelatine capsules are formed. Gelatine capsules manufactured according to the process provide retarded release of active ingredients.
The underlying problem of the invention is to provide an oral dosage form for poly-unsaturated acids comprising food, food supplement, and dietetics which provides a longer durability for the polyunsaturated acids. Furthermore, the oral dosage form should be admissible under food regulations.
The problem is solved with the features of claim 1.
According to the present invention, polyunsaturated acids are provided in gelatine capsules. The gelatine capsule is hardened with the help of xylose. The hardening provides a retarded opening time of the capsule from about 45 minutes and more Typically fatty acids are mixed with antioxidants such as tocopherole, ascorbyl-palmitate, propyl gallate and the like. The addition of antioxidants is avoided according to the invention because the xylose hardening prevents fat from "going bad". The peroxidation of the unsaturated acids is an important reaction for going bad of fat. Surprisingly, the dosage form according to the invention provides a low peroxidation, and a considerable delay in time for the fat to become rancid.
The oral dosage form according to the invention provides an undisturbed release of polyunsaturated acids in the intestine after passing the stomach. An unpleasant smell and flatulences are prevented.
.../3 Xylose is a well-known adjuvant in food industry which is inter alia re-claimable waste of the cellulose production. Xylose is also suitable as sweetening agent.
Furthermore, xylose has a laxative effect.
Omega-3 polyunsaturated acids with a high content of alpha linolenic acid, preferred perilla oil, can be used as polyunsaturated fatty acids. Also the use of fish oil, linseed oil, and gamma-linolenic acid is preferred.
The dosage form according to the invention is very well suited for essential fatty acids of all kinds which are delicate to formation of toxic radicals. For the use of the dosage form the following requirements hold:
- peroxide value < 2, - no advanced decomposition in the stomach or in the duodenum, - resorption in the small intestine.
Surprisingly all these requirements are achieved with the dosage form according to the invention.
According to a preferred embodiment of the invention the gelatine capsule is filled with perilla oil. Perilla oil is gained from the oil-containing fruits of the Asian plant perilla fructuence. The perilla oil contains more than 70% of unsaturated fatty acids, in particular a-linolenic acid.
A plurality of scientific studies has proven positive effects for the metabolism of fat (metabolic syndrome) and an antiphlogistic effect in the intestine (Morbus Crohn).
Perilla oil has furthermore the advantage of being almost without taste and smell.
.../4 Two galenic forms, a pure gelatine capsule and a xylose-hardened capsule, each containing perilla oil, have been tested for their peroxide value at 20°C and 45%
humidity for a time period of 12 months. The peroxide value of the xylose-hardened capsule was significantly lower than that of the pure gelatine capsule and did not increase during the testing period but even decreased.
In the study 24 persons took 3 to 6 capsules a 500 mg perilla oil over 4 weeks, no nausea, no stomach pressure, or other symptoms were observed. The persons' ability to taste was not reduced.
Example:
500 mg perilla oil capsule without xylose hardening during the long term test:
0 Months 3 Months6 Months 12 Months Perilla Oil / Perilla 498.2 506.2 513.5 486.1 Oil mg Perilla Oil / a-Linolenic260 264.2 268 253.7 Acid mg Peroxide Value 2.3 2.5 3.1 3 500 mg perilla oil capsule with xylose hardening during the long term test:
0 Months 3 Months6 Months 12 Months Perilla Oil / Perilla 498.7 508.1 513.8 489.2 Oil mg Perilla Oil / a-Linolenic260.3 265.2 268.2 255.5 Acid mg Peroxide Value 2.1 2.1 1.6 1 Blister packaging was used during the long term test.
./5 Xylose hardening can be achieved according to EP 0 240 581 B1, especially according to Example 3 of the specification. In an alternative approach it is possible to uniformly spray the capsule with a solution comprising xylose, ethanol and water for a predetermined time interval. During this time the capsules are heated.
After spraying a predetermined amount of hardening solution, the capsules are heat-treated for a predetermined time interval. The heat treatment causes the aldehyd function of the xylose to react with the gelatine and to provide a cross-linking. The cross-linking causes the hardening of the gelatine capsule. The finished product provides a struc-ture which inhibits the peroxidation of fatty acids so that the addition of antioxidants is unnecessary.
./6
Claims (13)
1. An oral dosage form for food, food supplements and dietetics comprising polyunsaturated fatty acids in a xylose-hardened gelatine capsule with a rewarded release time.
2. The dosage form as recited in claim 1, wherein said polyunsaturated fatty acids comprise omega-3 polyunsaturated fatty acids with a high content of alpha linolenic acid.
3. The dosage form as recited in claim 2, wherein the dosage form contains perilla oil.
4. The dosage form as recited in any one of claims 1 to 3, wherein said retarded release time is more than 45 minutes.
5. The dosage form according to any one of claims 1 to 4, wherein said dosage form is operative against diseases of metabolism of fat.
6. The dosage form according to any one of claims 1 to 5, wherein said dosage form is operative against intestinal inflammations.
7. The dosage form according to claim 6, wherein said intestinal inflammations comprise Morbus Crohn and colitis ulcerosa.
8. The dosage form according to claim 1, wherein the gelatine capsule comprises an ingredient selected from the group consisting of fish oil, linseed oil and gamma linolenic acid.
9. Use of a xylose-hardened gelatine capsule in order to prevent peroxidation of a polyunsaturated fatty acid contained in said gelatine capsule, wherein said gelatine capsule has a retarded release time and is used as oral dosage form for food, food supplements and dietetics.
10. The use as recited in claim 9, wherein said polyunsaturated fatty acid comprises omega-3 polyunsaturated fatty acids with a high content of alpha linolenic acid.
11. The use as recited in claim 10, wherein said gelatine capsule comprises perilla oil.
12. The use according to any one of claims 9 to 11, wherein said retarded release time is more than 45 min.
13. The use according to any one of claims 9 to 12, wherein said gelatine capsule comprises fish oil, linseed oil and gamma linolenic acid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19930030A DE19930030B4 (en) | 1999-06-30 | 1999-06-30 | Oral dosage form containing CO-3-unsaturated fatty acids |
| DE19930030.5 | 1999-06-30 | ||
| PCT/EP2000/003350 WO2001001797A1 (en) | 1999-06-30 | 2000-04-13 | Oral form of administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2335713A1 CA2335713A1 (en) | 2001-01-11 |
| CA2335713C true CA2335713C (en) | 2004-10-26 |
Family
ID=7913095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002335713A Expired - Fee Related CA2335713C (en) | 1999-06-30 | 2000-04-13 | Oral dosage form |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1091659B1 (en) |
| AT (1) | ATE217494T1 (en) |
| AU (1) | AU4295500A (en) |
| CA (1) | CA2335713C (en) |
| CZ (1) | CZ295721B6 (en) |
| DE (2) | DE19930030B4 (en) |
| HU (1) | HU230881B1 (en) |
| PL (1) | PL197477B1 (en) |
| WO (1) | WO2001001797A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPS088702A0 (en) * | 2002-03-04 | 2002-03-28 | Borody, Thomas Julius | Electrolyte purgative |
| GB0311081D0 (en) | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
| DE50302327D1 (en) * | 2003-11-06 | 2006-04-13 | Meduna Arzneimittel Gmbh | Gelatin capsule with fat-soluble vitamins and essential fatty acids |
| FR2865353B1 (en) * | 2004-01-23 | 2009-01-09 | Synergia Holding | NEW DIETETIC OR FOOD COMPLEMENTS BASED ON UNSATURATED FATTY ACID AND THEIR USE |
| GB0504362D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
| EP2081550B2 (en) | 2006-03-09 | 2021-05-26 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
| US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
| MX355760B (en) | 2010-12-13 | 2018-04-27 | Salix Pharmaceuticals Inc | Gastric and colonic formulations and methods for making and using them. |
| WO2013174884A1 (en) * | 2012-05-23 | 2013-11-28 | Capsugel France SAS | Capsules having an incorporated taste modifying component |
| JP6454640B2 (en) | 2012-07-27 | 2019-01-16 | レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． | Formulation for use in promoting colonic drainage and method for producing the formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3676491D1 (en) * | 1986-04-05 | 1991-02-07 | Scherer Gmbh R P | GELATINE CAPSULES WITH CONTROLLED ACTIVE SUBSTANCE RELEASE AND METHOD FOR THE PRODUCTION THEREOF. |
| GB2223943A (en) * | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
| US4936074A (en) * | 1988-11-17 | 1990-06-26 | D. M. Graham Laboratories, Inc. | Process for preparing solid encapsulated medicament |
| EP0623018B1 (en) * | 1992-01-17 | 1995-12-27 | ALFATEC-PHARMA GmbH | Process for the manufacture of soft gelatin capsules by a drip-feed method |
| GB9509764D0 (en) * | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
| JPH09201A (en) * | 1995-06-23 | 1997-01-07 | Akikuni Yakida | Food for inflammatory intestine disease |
| EP0841905A1 (en) * | 1995-08-02 | 1998-05-20 | Warner-Lambert Company | Hard gelatin capsules with low water transport and process for the production thereof |
| DE19611953A1 (en) * | 1996-03-26 | 1997-10-02 | Beiersdorf Ag | Use of unsaturated monocarboxylic acids against superinfections |
-
1999
- 1999-06-30 DE DE19930030A patent/DE19930030B4/en not_active Expired - Fee Related
-
2000
- 2000-04-13 AT AT00922634T patent/ATE217494T1/en active
- 2000-04-13 WO PCT/EP2000/003350 patent/WO2001001797A1/en not_active Ceased
- 2000-04-13 CZ CZ20014720A patent/CZ295721B6/en not_active IP Right Cessation
- 2000-04-13 DE DE50000168T patent/DE50000168D1/en not_active Expired - Lifetime
- 2000-04-13 PL PL353212A patent/PL197477B1/en not_active IP Right Cessation
- 2000-04-13 CA CA002335713A patent/CA2335713C/en not_active Expired - Fee Related
- 2000-04-13 AU AU42955/00A patent/AU4295500A/en not_active Abandoned
- 2000-04-13 HU HUP0201667A patent/HU230881B1/en unknown
- 2000-04-13 EP EP00922634A patent/EP1091659B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0201667A3 (en) | 2003-02-28 |
| EP1091659B1 (en) | 2002-05-15 |
| DE19930030A1 (en) | 2001-01-11 |
| HU230881B1 (en) | 2018-11-29 |
| CZ295721B6 (en) | 2005-10-12 |
| CZ20014720A3 (en) | 2002-05-15 |
| AU4295500A (en) | 2001-01-22 |
| PL197477B1 (en) | 2008-04-30 |
| ATE217494T1 (en) | 2002-06-15 |
| DE19930030B4 (en) | 2004-02-19 |
| WO2001001797A1 (en) | 2001-01-11 |
| DE50000168D1 (en) | 2002-06-20 |
| HUP0201667A2 (en) | 2002-09-28 |
| CA2335713A1 (en) | 2001-01-11 |
| EP1091659A1 (en) | 2001-04-18 |
| PL353212A1 (en) | 2003-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU778507B2 (en) | Formulation for menopausal women | |
| GB2223943A (en) | Oral disage forms of omega-3 polyunsaturated acids | |
| RU2009126735A (en) | COMPOSITION OF NUTRITIONAL SUPPLEMENT FOR THE TREATMENT OF EYE DISEASES | |
| JP2008501686A (en) | Nutritional product | |
| JP2009541433A (en) | Pharmaceutical compositions for oral administration of omega polyene fatty acids, and one or more incompatible ingredients and the process of their preparation | |
| CA2335713C (en) | Oral dosage form | |
| KR101380652B1 (en) | Enteric coated soft capsule composition containing purified fish oil and its preparation method | |
| US20130224304A1 (en) | Effervescent nutritional and/or dietary supplement composition | |
| RU2007117803A (en) | EYE TREATMENT COMPOSITION CONTAINING OMEGA-3 FATTY ACIDS AND OMEGA-6 FATTY ACIDS | |
| US7264824B1 (en) | Oral dosage form | |
| JPH11116475A (en) | Preventive and/or curing agent for inflammatory bowel disease | |
| FR2705233A1 (en) | New dosage forms permitting the differential timed release of combinations of micronutrients used in dietetics and/or therapy | |
| AU2005200907B2 (en) | Formulation for menopausal women | |
| CA2492417C (en) | Formulation for menopausal women | |
| JP2025511778A (en) | Softgel capsules having a fill composition comprising magnesium oxide | |
| CA3185451A1 (en) | Nutraceutic composition containing limonene and a dry extract of cocoa fibre for the treatment of obesity | |
| IES950246A2 (en) | Anti-oxidant formulations | |
| HK1055222B (en) | Ingestible compositions containing an odoriferous oil | |
| HK1055222A1 (en) | Ingestible compositions containing an odoriferous oil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150413 |